Nicotine vs Tobacco: What the Evidence Actually Says

In this sneak peek of AMA 70, Peter Attia returns to nicotine four years after his first conversation on the topic — this time focused on practical questions rather than mechanisms. He opens with the core confusion: nicotine is one of many compounds in the tobacco leaf, but the diseases most associated with tobacco are driven by other components of the plant and its smoke, including toxic metals, formaldehyde and polycyclic aromatic hydrocarbons.

A point he says he underappreciated four years ago is that extracting nicotine from tobacco does not automatically leave the carcinogens behind, because curing and fermentation generate byproducts that can travel with the product. The closer a product still looks and behaves like tobacco leaf, the higher those levels tend to run, which is why chewing tobacco and snus sit far worse on his ladder than a synthetic pouch. He walks through rodent studies where high nicotine doses increased tumor growth, metastasis and atherosclerotic plaque, while cautioning about the distance between those models and humans.

The closest human-adjacent evidence he found is a 2024 Mendelian randomization using nicotine-metabolism genes as a proxy for exposure, where the added disease risk disappeared once smoking heaviness was accounted for. He also notes mechanistic signals around the endothelium and an evidence gap in fertility research, where the data are rich for smoking and thin for pouches and vaping. Throughout, he stays firm on one point: nicotine is highly addictive, and the sharpness people report can quietly become the sharpness they lose when they go without it.

• 1

  Know the ladder of formats 0:20

  Attia places FDA-approved patches and gums at the top for safety, tobacco-free pouches just beneath, and e-cigarettes a clear step down. Anything that still resembles the leaf sits lowest.

• 2

  Check whether it is synthetic 5:45

  Whether nicotine is tobacco-derived or synthetic changes the processing byproducts that may come along with it. It is a label question worth asking before assuming a product is clean.

• 3

  Treat addiction as the headline risk 9:20

  Of everything discussed, dependence is the risk Attia states without hedging. Any decision about nicotine should start there rather than with the performance conversation.

• 4

  Read additives for what they are 12:10

  Most additives in approved nicotine replacement products exist for flavour, texture, stabilization and absorption. Knowing their purpose helps separate formulation choices from health signals.

• 5

  Ask what a study adjusted for 17:30

  The Mendelian randomization only became informative once smoking heaviness was factored out. When you read nicotine headlines, look for whether smoking was separated from the molecule.

• 6

  Mind the fertility evidence gap 21:00

  Data on smoking and fertility are extensive, while data on pouches and vaping are not. Absence of findings here reflects absence of research, not a clean bill of health.

• 7

  Notice the moving baseline 22:50

  People often report feeling sharper on nicotine, but as dependency grows that feeling can shift into what is missing without it. Watching your own baseline matters more than the initial effect.